The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling

Journal of Clinical Investigation

Volumn 118, Issue 1, 2008, Pages 64-78

  Brantley Sieders, Dana M ^a   Zhuang, Guanglei ^a   Hicks, Donna ^a   Wei, Bin Fang ^a   Hwang, Yoonha ^a   Cates, Justin M M ^a   Coffman, Karen ^b   Jackson, Dowdy ^b   Bruckheimer, Elizabeth ^b   Muraoka Cook, Rebecca S ^c   Chen, Jin ^a,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; INGUINAL LYMPH NODE; MAMMARY GLAND; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; RECEPTOR, EPHA2; RECEPTOR, ERBB-2; RHO GTP-BINDING PROTEINS;

EID: 38149137411     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33154     Document Type: Article

References (71)

1. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
2. Hahn, W.C., and Weinberg, R.A. 2002. Rules for making human tumor cells. N. Engl. J. Med. 347:1593-1603.
3. Vogelstein, B., and Kinzler, K.W. 2004. Cancer genes and the pathways they control. Nat. Med. 10:789-799.
4. Blume-Jensen, P., and Hunter, T. 2001. Oncogenic kinase signalling. Nature. 411:355-365.
5. Brantley-Sieders, D.M., and Chen, J. 2004. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis. 7:17-28.
6. Brantley-Sieders, D., Parker, M., and Chen, J. 2004. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr. Pharm. Des. 10:3431-3442.
7. Ireton, R.C., and Chen, J. 2005. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr. Cancer Drug Targets. 5:149-157.
8. Brantley-Sieders, D.M., et al. 2005. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J. 19:1884-1886.
9. Murai, K.K., and Pasquale, E.B. 2003. 'Eph'ective signaling: forward, reverse and crosstalk. J. Cell Sci. 116:2823-2832.
10. Poliakov, A., Cotrina, M., and Wilkinson, D.G. 2004. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev. Cell. 7:465-480.
11. Pasquale, E.B. 2005. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 6:462-475.
12. Zelinski, D.P., et al. 2001. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 61:2301-2306.
13. Duxbury, M.S., Ito, H., Zinner, M.J., Ashley, S.W., and Whang, E.E. 2004. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 23:1448-1456.
14. Landen, C.N., Jr., et al. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:6910-6918.
15. Nasreen, N., Mohammed, K.A., and Antony, V.B. 2006. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer. 107:2425-2435.
16. Fang, W.B., Brantley-Sieders, D.M., Parker, M.A., Reith, A.D., and Chen, J. 2005. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene. 24:7859-7868.
17. Brantley, D.M., et al. 2002. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 21:7011-7026.
18. Cheng, N., et al. 2003. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia. 5:445-456.
19. Dobrzanski, P., et al. 2004. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 64:910-919.
20. Pratt, R.L., and Kinch, M.S. 2002. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene. 21:7690-7699.
21. Pratt, R.L., and Kinch, M.S. 2003. Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. Mol. Cancer Res. 1:1070-1076.
22. Guo, H., et al. 2006. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res. 66:7050-7058.
23. Miao, H., et al. 2001. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell Biol. 3:527-530.
24. Macrae, M., et al. 2005. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell. 8:111-118.
25. Dohn, M., Jiang, J., and Chen, X. 2001. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene. 20:6503-6515.
26. Zhang, W., et al. 2003. Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2. Cancer Biol. Ther. 2:572-578.
27. Yang, G., Zhang, G., Pittelkow, M.R., Ramoni, M., and Tsao, H. 2006. Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. J. Invest. Dermatol. 126:2490-2506.
28. Jin, Y.J., et al. 2006. A novel mechanism for p53 to regulate its target gene ECK in signaling apoptosis. Mol. Cancer Res. 4:769-778.
29. Guy, C.T., Cardiff, R.D., and Muller, W.J. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954-961.
30. Guy, C.T., et al. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U. S. A. 89:10578-10582.
31. Muraoka, R.S., et al. 2003. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol. Cell. Biol. 23:8691-8703.
32. Eccles, S.A. 2001. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J. Mammary Gland Biol. Neoplasia. 6:393-406.
33. Muthuswamy, S.K., Li, D., Lelievre, S., Bissell, M.J., and Brugge, J.S. 2001. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 3:785-792.
34. Ueda, Y., Wang, S., Dumont, N., Yi, J.Y., Koh, Y., and Arteaga, C.L. 2004. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J. Biol. Chem. 279:24505-24513.
35. Olson, M.F., Ashworth, A., and Hall, A. 1995. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 269:1270-1272.
36. Welsh, C.F., et al. 2001. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat. Cell Biol. 3:950-957.
37. Lin, E.Y., et al. 2003. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163:2113-2126.
38. Ogawa, K., et al. 2000. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene. 19:6043-6052.
39. Pan, M. 2005. Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 23(Suppl.):9583.
40. Lu, M., Miller, K.D., Gokmen-Polar, Y., Jeng, M.H., and Kinch, M.S. 2003. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 63:3425-3429.
41. Duxbury, M.S., Ito, H., Zinner, M.J., Ashley, S.W., and Whang, E.E. 2004. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem. Biophys. Res. Commun. 320:1096-1102.
42. Dankort, D.L., and Muller, W.J. 2000. Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene. 19:1038-1044.
43. Ichaso, N., and Dilworth, S.M. 2001. Cell transformation by the middle T-antigen of polyoma virus. Oncogene. 20:7908-7916.
44. Zhuang, G., Hunter, S., Hwang, Y., and Chen, J. 2007. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J. Biol. Chem. 282:2683-2694.
45. Noblitt, L.W., et al. 2004. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther. 11:757-766.
46. Walker-Daniels, J., Riese, D.J., 2nd, and Kinch, M.S. 2002. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol. Cancer Res. 1:79-87.
47. Wang, Y., et al. 2002. Negative regulation of EphA2 receptor by Cbl. Biochem. Biophys. Res. Commun. 296:214-220.
48. Carles-Kinch, K., Kilpatrick, K.E., Stewart, J.C., and Kinch, M.S. 2002. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res. 62:2840-2847.
49. Landen, C.N., Jr.,et al. 2006. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl. Cancer Inst. 98:1558-1570.
50. Kiewlich, D., et al. 2006. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia. 8:18-30.
51. Penichet, M.L., et al. 1999. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49:179-188.
52. Ursini-Siegel, J., Schade, B., Cardiff, R.D., and Muller, W.J. 2007. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer. 7:389-397.
53. Tang, C.K., Gong, X.Q., Moscatello, D.K., Wong, A.J., and Lippman, M.E. 2000. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 60:3081-3087.
54. Brandt, R., et al. 2000. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene. 19:2129-2137.
55. Larsen, A.B., et al. 2007. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol. Cancer Res. 5:283-293.
56. Klijn, J.G., Berns, P.M., Schmitz, P.I., and Foekens, J.A. 1992. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 13:3-17.
57. Klijn, J.G., et al. 1994. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res. Treat. 29:73-83.
58. Wikstrand, C.J., et al. 1995. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:3140-3148.
59. Ge, H., Gong, X., and Tang, C.K. 2002. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int. J. Cancer. 98:357-361.
60. Tsutsui, S., et al. 2003. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery. 133:219-221.
61. Rae, J.M., et al. 2004. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res. Treat. 87:87-95.
62. Cheng, N., and Chen, J. 2001. Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism. J. Biol. Chem. 276:13771-13777.
63. Brantley-Sieders, D.M., et al. 2004. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J. Cell Sci. 117:2037-2049.
64. Bergers, G., et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:737-744.
65. Brantley, D.M., et al. 2001. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell. 12:1445-1455.
66. Muraoka-Cook, R.S., et al. 2004. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64:9002-9011.
67. Muraoka, R.S., et al. 2002. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 22:2204-2219.
68. Brantley-Sieders, D.M., Fang, W.B., Hwang, Y., Hicks, D., and Chen, J. 2006. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res. 66:10315-10324.
69. Brummelkamp, T.R., Bernards, R., and Agami, R. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:550-553.
70. Debnath, J., Muthuswamy, S.K., and Brugge, J.S. 2003. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 30:256-268.
71. Spancake, K.M., et al. 1999. E7-transduced human breast epithelial cells show partial differentiation in three-dimensional culture. Cancer Res. 59:6042-6045.